Loading...
•
Mar 31, 2021
Lineage Q1 2021 Earnings Report
Reported financial results for the first quarter of 2021 and highlighted significant progress with all three clinical programs.
Key Takeaways
Lineage Cell Therapeutics reported significant operational progress with its three clinical programs, including positive clinical results with OpRegen and strategic collaborations for OPC1 and VAC programs. The company is well funded to reach additional milestones due to capital raised during the quarter.
Lineage delivered continued positive clinical results with OpRegen for the treatment of dry-AMD with GA.
Partnerships were validated to support OPC1 and VAC programs.
Strategic collaborations for OPC1 and VAC reflect commitment to a comprehensive asset management approach.
Capital brought in during the first quarter ensures the company is well funded to reach additional milestones.
Lineage
Lineage
Forward Guidance
Lineage anticipates continued progress with clinical trials, data presentations, and potential partnerships.
Positive Outlook
- Anticipated funding runway
- Data presentations
- Clinical trial advancement
- Meetings and interactions with the FDA
- Manufacturing improvements
Challenges Ahead
- Risks and uncertainties inherent in Lineage’s business
- Risks in Lineage’s filings with the Securities and Exchange Commission (the SEC)
- Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect.
- All forward-looking statements are expressly qualified in their entirety by these cautionary statements.
- Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.